Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Enliven Therapeutics, Inc. has received an average consensus rating of "Buy" from five brokerages, with a 1-year price target of $41.20.
• Insider transactions indicate that executives have sold shares recently, with COO Anish Patel selling 6,667 shares and CEO Samuel Kintz selling 5,000 shares, reflecting a slight decrease in their ownership.
• Despite a recent drop of 3.7% in stock price, the company reported a lesser-than-expected loss in earnings, with a consensus EPS estimate of ($1.95) for the current fiscal year.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has received a consensus rating of "Buy" from the five ratings firms that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $41.20.

Several brokerages have recently commented on ELVN. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Robert W. Baird increased their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Finally, HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd.

Insiders Place Their Bets

In related news, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.24, for a total value of $134,940.08. Following the completion of the sale, the chief operating officer directly owned 283,308 shares of the company's stock, valued at approximately $5,734,153.92. This represents a 2.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 5,000 shares of the stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $19.09, for a total value of $95,450.00. Following the completion of the sale, the chief executive officer directly owned 922,892 shares of the company's stock, valued at approximately $17,618,008.28. This represents a 0.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 92,234 shares of company stock valued at $1,892,244 in the last 90 days. Insiders own 25.90% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enliven Therapeutics by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock worth $451,000 after purchasing an additional 718 shares in the last quarter. Invesco Ltd. raised its stake in shares of Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in shares of Enliven Therapeutics by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after purchasing an additional 1,940 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Down 3.7%

Shares of NASDAQ ELVN opened at $19.19 on Wednesday. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $30.03. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -9.60 and a beta of 0.89. The business has a fifty day simple moving average of $20.00 and a 200-day simple moving average of $19.63.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, sell-side analysts expect that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.